KINEX LABS products are sold exclusively for in-vitro research and laboratory use. By entering, you confirm you are 18 or older and a qualified researcher, and you will not use these compounds for human consumption.
Retatrutide 20 mg is a higher-concentration format of the triple-agonist peptide Retatrutide. Each vial contains 20 mg of lyophilized peptide for research applications requiring larger working stock.
Research Profile
Triple-agonist activity across GIP, GLP-1, and glucagon receptors
Studied in metabolic, energy-balance, and glucose-handling research models
Larger vial format for high-throughput studies
QC verified by HPLC and mass spectrometry
Specifications
Compound: Retatrutide (LY3437943)
Dosage: 20 mg per vial
Purity: ≥ 98% (HPLC)
Form: Lyophilized powder
Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
